We have a robust and expanding pipeline of potential medicines in areas that represent unmet medical need.
We are building a strong and balanced pipeline with both small molecules and biologics. We have achieved the portfolio breadth we require to launch on average 2 NCEs per year from 2010 onwards.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 23:35 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
